**8. Conclusion**

BSGI/MBI and PEM are adjunctive molecular breast imaging technologies which are becoming more common in the breast center and they provide very similar performance in terms of sensitivity and specificity. The radiation dose associated with these imaging techniques is similar to that patients receive from other diagnostic imaging procedures such

The Role of Molecular Imaging Technologies in Breast Cancer Diagnosis and Management 195

Cutrone, J.A., Yospur, L.S., Khalkhali, I., Tolmos, J., Devito, A. & Diggles, L. (1998).

Goldsmith, S., et al. (2010). SNM Practice Guideline for Breast Scintigraphy with Breast-

Hendrick, E. (2010) Radiation doses and cancer risks from breast imaging studies. *Radiology*.

Hruska, C.B., Phillips, P.W., Whaley, D.H., Rhodes, D.J. & O'Connor, M.K. (2008) Molecular

Khalkhali, I., et al. (2004). Society of Nuclear Medicine Procedure Guideline for Breast

Kolb, T.M., Lichy, J. & Newhouse, J.H. (2002) Comparison of the performance of screening

Lee, A., Lee, J., Chang, J., Lim, W., Kim, B., Lee, B. & Moon, B. (2011). The efficacy of Breast-

Lin, C., Ding, H., et al. (2007) Correlation Between the Intensity of Breast FDG Uptake and

MacDonald, L., Luo, W., Lu, X., Wang, C. & Rogers, J. (2010) Low Dose Lesion Contrast on

O'Connor, M., Li, H., Rhodes, D.H., Hruska, C.B., Clancy, C.B., Vetter, R.J. (2010).

Piwnica-Worms, D., Kronauge, J.F. & Chiu, M.L. (1990). Uptake and retention of hexakis (2-

Rosen, E., Turkington, T., Soo, M.S., Baker, J.A. & Coleman, R.E. (2005). Detection of Primary

Schelbert, H., et al. Society of Nuclear Medicine Procedure Guideline for Tumor Imaging

Philadelphia Pennsylvania, USA, July 18-22, 2010. ISSN 0094-2405

No.12, (December 2010), pp. 6187-1689, ISSN 0094-2405

No.5, (November 1990), 1826–1838. ISSN 0009-7322

http://interactive.snm.org/docs/pg\_ch28\_0403.pdf. 1999.

Breast Imaging: Use of a Dual-Head Dedicated Gamma Camera to Detect Small Breast Tumors. *American Journal of Roentgenology*, Vol.191 No.6, (December 2008)

mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. *Radiology*, Vol.225, No.1,

Specific Gamma Imaging with 99mTc-Sestamibi in the diagnosis of breast cancer according to breast density for Korean women. *Yellow Sea International Medical* 

Menstrual Cycle. *Academic Radiology,* Vol.14, No.8, (August 2007), pp. 940–944,

the PEM Flex Solo II. *Medical Physics, Proceedings of the Fifty-second Annual Meeting of the American Association of Physicist in Medicine*, Vol.37, No.6, (July 2010)

Comparison of radiation exposure and associated radiation-induced cancer risks from mammography and molecular imaging of the breast. *Medical Physics.* Vol.37,

methoxyisobutyl isonitrile) technetium in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. *Circulation,* Vol.82,

Breast Carcinoma with a Dedicated, Large-Field-of-View FDG PET Mammography Device: Initial Experience. *Radiology*, Vol.234, No.2, (February 2005), pp. 527–534.

http://interactive.snm.org/docs/BreastScintigraphyGuideline\_V1.0.pdf

Vol.257, No.1, (October 2010), pp. 246-53, ISSN 0033-8419

http://interactive.snm.org/docs/Breast\_v2.0.pdf. (June 2004)

*Biennial symposium,* Kintex, Korea, January 22, 2011

pp. 449–453, ISSN 0161-5505

ISSN 1546-3141

ISSN 1076-6332

ISSN 0033-8419

Using F-18 FDG. Available from

Specific -Cameras 1.0. Available from

Scintigraphy 2.0. Available from

pp. 165–175. ISSN 0033-8419

Immunohistologic assessment of technetium-99m-MIBI uptake in benign and malignant breast lesions. *Journal of Nuclear Medicine.* Vol.39, No.3, (March 1998),

as CT, PET and nuclear medicine thus their use is currently limited to the diagnostic patient population. However, several studies are underway to reduce the radiation dose to the level of screening mammography which will likely increase their utility to breast cancer screening in the asymptomatic population. The BSGI/MBI procedure is a useful problem-solving tool for patients with dense or complex breast tissue and an unresolved diagnostic concern following anatomical imaging procedures such as mammography and ultrasound. Both BSGI/MBI and PEM are useful in breast cancer patients to detect the extent of disease (additional occult multifocal or muticentric disease) and to monitor tumor response to neoadjuvant chemotherapy. PEM has the advantage of tomographic reconstruction and uniform spatial resolution with increasing tumor depth. In addition, for the breast cancer patient undergoing a PET/CT scan for staging, it is possible to conduct the PEM study following the PET/CT without an additional administration of FDG. The advantages for BSGI/MBI are superior photon sensitivity along the chest wall, fewer patient restrictions and the wider availability of MIBI (see the considerations section above).

#### **9. References**


as CT, PET and nuclear medicine thus their use is currently limited to the diagnostic patient population. However, several studies are underway to reduce the radiation dose to the level of screening mammography which will likely increase their utility to breast cancer screening in the asymptomatic population. The BSGI/MBI procedure is a useful problem-solving tool for patients with dense or complex breast tissue and an unresolved diagnostic concern following anatomical imaging procedures such as mammography and ultrasound. Both BSGI/MBI and PEM are useful in breast cancer patients to detect the extent of disease (additional occult multifocal or muticentric disease) and to monitor tumor response to neoadjuvant chemotherapy. PEM has the advantage of tomographic reconstruction and uniform spatial resolution with increasing tumor depth. In addition, for the breast cancer patient undergoing a PET/CT scan for staging, it is possible to conduct the PEM study following the PET/CT without an additional administration of FDG. The advantages for BSGI/MBI are superior photon sensitivity along the chest wall, fewer patient restrictions

Avril, N., Menzel, M., Dose, J., Schelling, M., et al. (2001). Glucose Metabolism of Breast

Ballinger, J.R., Hua, H.A., Berry, B.W., Firby, P. & Boxen, I. (1995). 99Tcm-Sestamibi as an

Berg, W.A., Weinberg, I.N., Narayanan, D., Lobrano, M.E., Ross, E., Amodei, L., Tafra, L.,

*Breast Journal*. Vol.12, No.4, (July 2006), pp. 309-323, ISSN 1524-4741 Bertrand. M., Lanzkowsky, L., Stern, L. & Weigert, J. (2009). Results of a Multi-Center

Washington D.C. USA, April 21-22, 2011.

Cancer Assessed by 18F-FDG PET: Histologic and Immunohistochemical Tissue Analysis. *Journal of Nuclear Medicine,* Vol.42*,* No.1*,* (January 2001), *pp.*9–16, ISSN

agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. *Nuclear Medicine Communications.* Vol.16, No.4, (April 1995), pp. 253–257, ISSN

Adler, L.P., Uddo, J., Stein, W. & Levine, E.A. (2006). High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer.

Patient Registry to Determine the Clinical Impact of Breast-Specific Gamma Imaging: A Molecular Breast Imaging Technique. *Radiologic Society of North America Annual Meeting*. Chicago, Illinois, USA, November 29 – December 4, 2009. Böhm-Vélez, M., Kieper, D.A., Williams, M.B., Chang, T.S., Ward, B.H. & Straka, M.R. (2011)

A Clinical Evaluation of Breast Tissue Uptake of Tc99m-Sestamibi as a Function of Injected Dose. *Breast Cancer Imaging: State of the Art 2011 – Poster Abstracts, Journal of Nuclear Medicine*, Vol.52, No.4, (April 2011) pp. 660-675. ISSN 0161-5505,

Gamma Imaging as an Adjunct Imaging Modality for the Diagnosis of Breast

and T1201 in unsuspected breast tumor. (1992). *Clinical Nuclear Medicine,* Vol.17,

Brem, R., Floerke, A., Rapelyea, J., Teal, C., Kelly, T. & Mathur, V. (2008). Breast Specific

Cancer. *Radiology.* Vol.247, No.3 (June 2008), pp. 651-57, ISSN 0033-8419 Campeau, R..J, Kronemer, K.A. & Sutherland, C.M. Concordant uptake of Tc-99m sestamibi

and the wider availability of MIBI (see the considerations section above).

**9. References** 

0161-5505

0143-3636

pp. 936-937


http://interactive.snm.org/docs/BreastScintigraphyGuideline\_V1.0.pdf


http://interactive.snm.org/docs/Breast\_v2.0.pdf. (June 2004)


http://interactive.snm.org/docs/pg\_ch28\_0403.pdf. 1999.

**Part 2** 

**Clinical Implications** 

